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ABSTRACT
Human beings have taken successive approaches for the understanding and management of diseases. Initially brewed in
supernatural concepts and mystical procedures, a vigorous scientific approach has emerged on the grounds of fundamen-
tal disciplines such as anatomy, microbiology, biochemistry, physiology, immunology, pathology, and pharmacology.
The resulting integrated knowledge contributed to the current classification of diseases and the way Medicine is carried
out today. Despite considerable progress, this approach is rather insufficient when it comes to systemic inflammatory
conditions, such as systemic lupus erythematosus, that covers clinical conditions ranging from mild pauci-symptomatic
diseases to rapidly fatal conditions. The treatment for such conditions is often insufficient and novel approaches are
needed for further progress in these areas of Medicine. A recent breakthrough has been achieved with respect to chronic
auto-inflammatory syndromes, in which molecular dissection of underlying gene defects has provided directions for
target-oriented therapy. Such approach may be amenable to application in systemic auto-immune diseases with the
comprehension that such conditions may be the consequence of interaction of specific environmental stimuli and an ar-
ray of several and interconnected gene polymorphisms. On the bulk of this transformation, the application of principles
of pharmacogenetics may lead the way towards a progressively stronger personalized Medicine.
Key words: autoimmunity, pharmacogenetics, gene polymorphism, auto-inflammatory diseases, systemic lupus ery-
thematosus, rheumatoid arthritis.
HISTORICAL PERSPECTIVE IN DIAGNOSIS PARADIGM
Since ancient times, human beings have struggled to
provide help to those suffering from the diverse illnesses
that affect mankind and other living beings. Primitive
paradigms were mainly based on instinct, mysticism
and supernatural approaches. Dance rituals and magic
medicines were the answer that those early profession-
als provided to the sufferers. With the advent of the
early founders of the contemporary medical science in
the Mediterranean area, a rational, observational and
ethical approach was progressively established. Accord-
ingly, the diagnostic and therapeutic approaches were
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then modified towards more effective procedures,
including recommendations related to life style and hy-
giene. However, still at those early times the prevalent
theories for health and disease were largely based on
beliefs, such as the miasmas and circulating humors
(blood, phlegm, black and yellow bile). Therapeutic
interventions included baths at special temperatures,
boiling oil, ointments, bloodletting, suction cups, and
so on (Lyons and Petruccelli 1978).
With the advent of Renascence and the rising of
the contemporary scientific system, as we know it today,
different fields in natural sciences started to contribute
to a body of objective knowledge that ultimately led to
the establishment of the medical practice as we know
today. Anatomy, physiology, chemistry, microbiology,
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and other scientific fields contributed to the building of
a new body of knowledge that progressively allowed the
conception of novel medical paradigms that gradually
would replace the old ones. Miasmas and circulating
humors were not appropriate to the facts brought up by
objective investigations in microbiology, anatomy, phys-
iology, and the nascent clinical chemistry. The new con-
cepts would re-shape the established nosology (disease
classification system). The art of clinical examination
would also change with the aim of providing clues that
would guide physicians in classifying their patients ac-
cording to the new nosologic classification system. Aca-
demic clinical practice would feed back this emerging
nosologic classification system and vice-versa. In due
time, patients were diagnosed in a classification system
that included conditions such as bacterial pneumonia,
left heart failure, acute hepatitis, diabetes mellitus, gouty
arthritis, and so on.
It is common practice that the application of novel
paradigms into practical activities lags behind the scien-
tific advance pace. In fact, for a considerable period of
time, many of the involved professionals are bound to
reject the novel ideas or to under-estimate the magnitude
of the coming changes. To illustrate this point, let us
suppose that a regular physician from the 17th century
was to be confronted with a medical assessment of a fic-
tion patient as of today (Table I). We can easily expect
that this renascence mind would be confused with mixed
feelings of wonder and suspicion.
NOSOLOGIC CLASSIFICATION SYSTEM AS A FUNCTION
OF SCIENTIFIC AND TECHNOLOGICAL PROGRESS
Scientific paradigms, systematic classifications of phe-
nomena, and technology operate in an interactive mode
in which each one of these three elements influences the
progress of the other two (Fig. 1). Advances occurring
in any of these three elements are expected to influence
the two other elements. New methodological tools al-
low a closer look at the natural phenomena, which may
contribute to improve the classification of the system and
eventually confirm or challenge the established scientific
paradigm. Novel scientific paradigms push the develop-
ment of appropriate technology and demand novel clas-
sification systems. Examples of this kind of virtuous
loop can be found in the several revolutions in Physics
paradigms along the last four centuries. The same is true
for Biology and related areas, including Medicine.
Fig. 1 – Mutual and virtuous interaction among scientific paradigms,
technical advances, and classification systems.
CRITICAL APPRAISAL OF THE CURRENT NOSOLOGY OF
SYSTEMIC RHEUMATIC DISEASES
The current nosologic classification of systemic rheum-
atic diseases has emerged in the middle of the 20th cen-
tury. During the first decades of the last century, the
strong influence of Paul Erlich has pushed the scien-
tific community towards the concept of “horror auto-
toxicus”, which was erroneously understood as the im-
possibility of the immune system to recognize self-cons-
tituents. Systematic experimentation progressively dis-
closed, however, consistent evidence that, under certain
circumstances, the immune system may set up a vigorous
response against self tissues and organs. Some of these
seminal experiments included the immunization of rab-
bits with thyroid tissue that elicited auto-reactive T lym-
phocytes and the destruction of the thyroid gland by an
intense inflammatory infiltrate. In addition, the disease
could be transferred to healthy animals by inoculation
of lymphocytes from the immunized rabbits (Rose 1988,
Doniach and Roitt 1988).
As a hint on how intense was the dispute in this field,
one can evoke the episode in which the American hema-
tologist William Harrington self injected plasma from
a patient with putative immunologic thrombocytopenic
purpura. After a few hours, the platelet count started
falling down reaching a nadir of 7,000/mm3 coincident
with an episode of generalized tonic-clonic convulsion.
Fortunately, the devoted researcher recovered with no
major sequel (Harrington et al. 1951).
On a clinical basis, two contemporary discoveries
allowed the identification of serum factors with auto-
reactivity, namely the rheumatoid factor (Waller 1940)
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TABLE IFiction patient presented to a physician at the middle age era.
Systemic blood pressure: 150 × 95 mmHg
Blood hemoglobin: 9.5 g/dL
Blood lymphocyte count: 340/mm3
Serum gamma-glutamyl transferase: 24 U/L
Blood glucose: 93 mg/dL
Estimated systolic pressure in pulmonary artery: 75 mmHg
Capillary ectasia and deletion at the nailfold
Antinuclear antibody 1:640 with coarse speckled nuclear pattern
Anti-RNP antibodies: 1/10,240
High-resolution thorax tomography → ground-glass images in lung bases
and the LE cell phenomenon (Hargraves et al. 1948).
These two pioneer autoantibodies set the road for a vig-
orous research field that would flourish for the whole
20th century (Tan 1997, Strassburg and Manns 2002,
Sherer et al. 2004). The steady progress in the demon-
stration of a series of clinically relevant autoantibodies
helped pave the way for the nosologic classification sys-
tem for the new family of diseases, the so-called autoim-
mune diseases (Chan and Andrade 1992, Tan and Chan
1993, Dellavance et al. 2005).
Nowadays, the concept of autoimmunity is well es-
tablished (Schwartz 1993). Diseases with widespread
involvement are classified as non-organ specific autoim-
mune diseases. Examples of these include systemic lu-
pus erythematosus (SLE), systemic sclerosis, dermato-
myositis, polymyositis, rheumatoid arthritis, and Sjö-
gren’s syndrome. Those with a more restricted organ
involvement are designated organ-specific autoimmune
diseases. Examples of these are autoimmune thyroidi-
tis, pemphigus vulgaris, myasthenia gravis, autoimmune
hepatitis, and chronic biliary cirrhosis. Although this
classification system has provided a reasonable frame-
work to differentiate and manage these patients, it is not
without flaws. In fact the extent to which a given dis-
ease is restricted to a certain organ is quite variable and
many organ-specific autoimmune conditions present var-
ious degrees of systemic involvement. We can take au-
toimmune hepatitis type I as an example, in which skin
and joint involvement is quite frequent (Manns and Vo-
gel 2006). On the other hand, some of the non-organ
specific autoimmune diseases frequently come into view
as a quite restricted illness. A good example is Sjögren’s
syndrome, in which many patients show evidence of re-
stricted involvement of salivary and lachrymal exocrine
glands (Fox 2005, Barcellos et al. 2007). Rheumatoid
arthritis and polymyositis are also frequently restricted
to sinovial joints and skeletal muscles, respectively
(Bouysset et al. 2005, Briani et al. 2006).
Another problematic point in the current classifi-
cation system is that many patients present features that
overlap two or more of the defined autoimmune diseases.
It is not unusual, for example, that a patient with SLE
presents isolated features suggestive of systemic scle-
rosis, such as swollen fingers, Raynaud’s phenomenon,
and esophageal dismotility (Furtado et al. 2002). In
some cases, there is concomitant full-blown presenta-
tion of two or more of these conditions. The current
classification system accommodates those cases as over-
lap syndromes (Rodriguez-Reyna and Alarcon-Segovia
2006). In addition, the association of an organ-specific
and a non-organ specific disease is quite frequent. For
example, patients with rheumatoid arthritis are frequently
affected by thyroid autoimmune diseases (Somers et al.
2006).
However, the most crucial deficiency in the current
autoimmune disease classification system is the failure in
appropriately addressing the large heterogeneity within
each nosologic entity. The diagnosis of SLE per se, for
example, is not enough to provide an accurate idea of
the prognosis of that particular patient or of what kind
of treatment should be started. There is a wide clini-
cal spectrum within this diagnostic label. Some patients
will present a mild skin rash with arthralgia and oc-
casional arthritis, will demand mild therapy, and will
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suffer no major impact on life style and no major in-
terference with life perspectives. Some other patients
with SLE may present serositis, thrombocytopenia, de-
forming skin involvement, and incapacitating fatigue.
These may experience considerable interference with
life style and professional and social performance. Fi-
nally, some other patients equally diagnosed as SLE
may present severe and life-threatening manifestations,
such as CNS vasculitis, alveolar hemorrhage or severe
class IV glomerulonephritis. These few examples show
clearly that it is not enough to say that a given patient
has SLE. An accurate nosologic classification system
should be able to narrow down the spectrum of manifes-
tations expected for that diagnostic label and, therefore,
allow for an accurate prediction of the disease course
and the correspondent therapeutic planning for the pa-
tient (Fig. 2). Part of the complexity of disease phe-
notype is determined by non-genetic elements, such as
environmental exposure, life style, quality of the medi-
cal care, compliance to the treatment, social and cultural
level and existing co-morbidity. However, lessons from
animal models and from clinical research have pointed
that gene polymorphism also plays an important role in
the determination of specific autoimmune phenotypes.
Fig. 2 – Unraveling well-defined sub-phenotypes underneath broad-
label general syndromes. Different patients with the label of a general
syndrome (upper panel), like SLE for example, present specific clini-
cal presentations with peculiar prognostic and therapeutic implications
(lower panel).
Should the SLE entity be split into several other
nosologic units? Should the SLE label be abandoned?
What kind of novel nosologic entities should be defined?
Could the same reasoning be appropriate for other au-
toimmune diseases, such as rheumatoid arthritis, sys-
temic sclerosis, polymyositis, and autoimmune liver
diseases?
It seems that our contemporary body of knowledge
and available technology are clearly not suitable for
such a reformulation of the current autoimmune diseases
classification system. However, one can always take the
neighbor’s experience as a perspective for one’s own de-
velopment. In fact, the case of the familial periodic fever
syndromes, the so-called auto-inflammatory syndromes,
may provide a clue to the diagnosis dissection needed
for the field of autoimmune diseases.
THE EXAMPLE OF THE AUTO-INFLAMMATORY
SYNDROMES
The recent development in the field of the hereditary
auto-inflammatory syndromes is quite exciting. For
many decades, the Mediterranean familial fever was the
only form of hereditary periodic fever syndrome to be
clinically and epidemiologically individualized. Over
the past 10 years or so, other members of this family of
conditions, now designated as auto-inflammatory syn-
dromes, have been defined at the molecular level.
The hereditary periodic fever syndromes are char-
acterized and defined by the following features: recurrent
and self-limited episodes of fever and systemic inflam-
mation with no apparent cause; variable involvement of
skin, joints, serous membranes and internal organs; the
presence of hereditary component; and the development
of amyloidosis as a late complication (Grateau 2004).
The prototypic and most common auto-inflammatory
syndrome is Familial Mediterranean Fever. As suggested
by the name, it affects predominantly subjects with de-
scent from the Mediterranean area. It is an autosomal re-
cessive condition caused by mutations in the MEFV gene
in region 16p13.3. Heterozygous subjects may present
mild traits of the disease. The MEFV gene codes for
marenostrin, a protein that is able to modulate the ef-
fect of caspase 1 on the transcription regulation of IL-1β
gene. Mutations in MEFV gene may cause a deficient
inhibition of IL-1β expression and therefore induce a
pro-inflammatory status (Zaks et al. 2003, Schaner and
Gumucio 2005, Aróstegui et al. 2004).
Along the last decade, other idiopathic inflammat-
ory syndromes have been demonstrated to fulfill the
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TABLE IIMolecular definition of auto-inflammatory syndromes.
• Familial Mediterranean Fever
– 26 mutations in MEFV gene – 16p13.3 (most in exon 10, nt 680 & 694)
– Dysfunction of marenostrin (also known as pirin)
– Impaired inhibition of IL-1β
• Cold Induced Auto-Inflammatory Syndromes – 1 (CIAS-1)
– Mutations in CIAS-1 gene
– Dysfunction of criopirin → increase in IL-1β
– Muckle-Wells syndrome (MWS)
– Familial cold urticaria (FCU)
– Chronic Infantile Neurologic, Cutaneous and Articular Syndrome (CINCA) or
Neonatal Onset Multisystemic Autoinflammatory Disease (NOMID)
• Traps – Tnf Receptor Associated Periodic Syndrome
– Mutations in TNFRSF1A gene (12p13) → disturb the first two cystein-rich domains
of the 55-kDa TNF receptor
– The defective 55-kDa soluble TNF receptor is incapable of neutralizing TNF
• Hyper-Igd Syndrome
– Mutations in MVK gene (12q24) → deficiency in mevalonate Kinase → increase in IL-1β synthesis
requirements for classification as auto-inflammatory
syndromes and their underlying molecular defects have
been identified. These include the Cold Induced Auto-
inflammatory Syndromes – 1 (CIAS-1) (Aróstegui et
al. 2004), the TNF Receptor Associated Periodic Syn-
drome (TRAPS) (Masson et al. 2004, Aganna et al.
2003), and the Hyper-IgD syndrome (Prietsch et al.
2003). A preliminary list of molecular defects and
mechanisms of the auto-inflammatory syndromes is
depicted in Table II.
Would it be possible to adapt the molecular model
of the auto-inflammatory syndromes to the classifica-
tion of autoimmune diseases? The case of Autoimmune
Lymphoproliferative Syndrome (ALPS) is quite com-
pelling. This condition is characterized by adenomegaly,
splenomegaly, autoimmune cytopenias, autoantibodies,
and several SLE-like traits (reviewed in Worth et al.
2006). It is caused by mutations in genes involved in
the Fas-mediated apoptosis pathway. Subtypes of ALPS
with subtle clinical differences have been identified ac-
cording to the specific molecular defect. Type Ia is
caused by mutations in the TNFRSF6 gene (Fas – CD-
95); type Ib is associated with mutations in the TNFSF6
gene (Fas ligand or CD-95 ligand); type 2a is associated
with mutations in the CASP10 gene (caspase 10); and
type 2b is caused by mutations in the CASP8 gene (cas-
pase 8) (Worth et al. 2006. Although ALPS may offer
a molecular definition for some cases labeled as SLE,
it is clear that the vast majority of SLE patients have
no defect in the Fas-mediated apoptosis pathway. How-
ever, other molecular mechanisms are long known to be
associated with SLE, as is the case for congenital defi-
ciency of early components of the complement system
(C1q, C2, and C4) (Worth et al. 2006). Still, these repre-
sent a negligible fraction of SLE patients. Nonetheless,
these examples are signaling that it may be possible to
segregate specific clinical phenotypes within a vast and
heterogeneous syndrome like SLE and to associate these
novel relatively homogeneous clinical phenotypes with
specific molecular defects. It has become progressively
evident that the genetic regulation of autoimmune dis-
eases is extremely complex, and that the establishment
of an autoimmune status is conditioned by the interac-
tion of several dozens of alleles. For the last 15 years,
an increasing number of gene polymorphisms has been
associated with susceptibility or specific clinical traits
in several autoimmune diseases. In the case of SLE,
for example, increased susceptibility has been associ-
ated with polymorphisms in the genes for IL-6, IL-10,
FcγRIIA, IIB, IIIA, IIIB, CLTA-4, PTPN22, Mannose
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binding lectin, angiotensin converting enzyme, DNase I,
among others (Alarcon-Riquelme 2005).
It is relevant for the present issue that the impor-
tance of gene polymorphism is not restricted to the de-
termination of disease susceptibility, but it has also been
associated with disease phenotype in human and murine
SLE (Nolsoe et al. 2005, Qi et al. 2005, Johansson et al.
2005). In that sense, gene polymorphism may indeed
contribute to the dissection of a general syndrome like
SLE into sub-phenotypes with distinct clinical, prog-
nostic and therapeutic features. However, it is increas-
ingly apparent that several gene polymorphisms must
concert interactively to modulate each specific pheno-
type. Notwithstanding this complexity, it is possible that
the most relevant genes involved in the determination
of a given autoimmune phenotype would be eventually
amenable to simultaneous analysis in some sort of mul-
tiplex platform. In fact, the challenge of a simultane-
ous and integrated analysis of multiple metabolic path-
ways is hard to be achieved with the standard research
methodology. In this respect, the novel and powerful
tools provided by large-scale methodological platforms
may prove to be helpful.
THE POTENTIAL CONTRIBUTION OF GENOMICS,
TRANSCRIPTOMICS AND PROTEOMICS
As opposed to the traditional approaches in biochem-
istry, microbiology, and immunology, the last two dec-
ades have brought large-scale methodologies that allow
the simultaneous analysis of thousands of parameters in
a single and even in multiple parallel biological speci-
mens. As opposed to the traditional approach of address-
ing a single or a few analytes, these methodological plat-
forms offer a comprehensive evaluation of hundreds or
thousands of parameters that are collectively expressed
as specific patterns associated with certain biological
conditions. These complex patterns are sometimes re-
ferred to as biological signatures. The science of pattern
recognition is long known and deals with the ability of
identifying an object or situation by the comprehensive
appreciation of the whole instead of the details (Bolin-
ger and Ahlers 1975). This kind of ability is responsi-
ble for the recognition of a familiar face, voice or land-
scape in which the overall pattern is more decisive than
each single parameter. Pattern recognition approach may
be applied to the definition of healthy and diseased bi-
ological states. These large-scale methodologies have
paved the way for the development of genomics, tran-
scriptomics, and proteomics according to the kind of an-
alyzed target, genomic DNA, messenger RNA, and pro-
teins, respectively.
Although the term is relatively new, proteomics
has been around for several decades. Classical Tiselius
electrophoresis and polyacrylamide gel electrophoresis
(PAGE), under reducing and non-reducing conditions,
were the first means of discriminating proteins in a com-
plex sample. The use of 2-dimensional electrophoresis
increased the discrimination power to an order of hun-
dreds or thousands. The use of antibodies as probes
in western blotting and Protein A-Sepharose facilitated
immunoprecipitation brought considerable specificity to
this approach. More recently, the use of mass spectrome-
try coupled to matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) has greatly increased the
power of proteomics analysis (Buetow et al. 2001). As
an example, the proteomic analysis of plasma may pro-
vide specific profiles for certain kinds of clinical condi-
tions, such as early breast and prostate cancer (Ornstein
et al. 2004, Martin 2006). A similar approach has been
applied to the definition of proteomic signature of the
inflammatory status in autoimmune conditions, such as
SLE and Wegener’s granulomatosis (Bennett et al. 2003,
Stone et al. 2005).
Genomics has allowed for the sequencing of the
genomes of hundreds of species, including the human
species. Detailed maps have been elaborated for known
genes, expressed sequence tags (ESTs), variable number
tandem repeats (VNTR), and single nucleotide polymor-
phisms (SNPs). These maps are fundamental tools for
linkage of the genetic information to disease susceptibil-
ity, disease phenotype, and pharmacogenetics (Belmont
and Gibbs 2004). In parallel, the planar array technol-
ogy has provided the possibility of probing one or more
biological samples for hybridization with thousands of
available sequences of the genome, thereby allowing the
establishment of specific patterns for biological samples
in terms of VNTR, SNPs, and other forms of gene poly-
morphism (Sosnowski et al. 2002, Frank 2002). This
methodology has greatly enhanced our ability in deter-
mining polymorphism of a myriad of genes in a single
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assay. The impact of this methodology may be readily
recognized by verifying the enormous number of publi-
cations on gene polymorphism of a great variety of genes
in the last 10 years, as compared with the primary focus
on polymorphism of the HLA system in the past decades.
The reverse transcription of sample messenger
RNA into complementary DNA (cDNA) has made it
possible to analyze the transcriptome, i.e., the gene ex-
pression pattern of a given biological sample. It is well
appreciated that the full repertoire of genes of a given
species is not used in each cell of the organism. In fact,
only a certain assembly of genes is expressed in a given
cell type and at a given physiologic status. The gene ex-
pression pattern of a given cell contributes to its specific
phenotype. For instance, erythroid precursors synthe-
size hemoglobin and neurons synthesize neurotransmit-
ters. As cells move from a physiologic to a pathologic
status, the gene expression pattern and the protein ex-
pression profile change accordingly. The cDNA microar-
ray technology has taken advantage of the gene expres-
sion pattern, to help distinguishing normal from tumoral
tissue in lung, breast, stomach and other forms of cancer
(Martin 2006, Brennan et al. 2005). Gene expression
and protein profile are expected to be also useful in
monitoring the therapeutic gene modulation in several
conditions (Wulfkuhle et al. 2004). In SLE, microar-
ray analysis of peripheral blood mononuclear cells has
allowed the definition of a characteristic expression sig-
nature associated with genes regulated by Type I IFN,
and this pattern is associated with disease activity (Bel-
mont and Gibbs 2004). Proteomic analysis of biological
samples has been also applied to the detection of several
types of cancer (Ornstein et al. 2004, Liotta and Petri-
coin 2006) and to the assessment of the activity status of
certain inflammatory diseases (Stone et al. 2005).
These novel tools have readily contributed to the
understanding and managing of diseases associated with
cancer and simple genetic syndromes. Applications of
this methodology are emerging also for the field of
autoimmune diseases. The determination of polymorph-
isms in genes for cytokines, chemokines, cell surface re-
ceptors, adhesion molecules, and downstream signaling
molecules has been intensively analyzed in several au-
toimmune diseases with respect to disease susceptibility
and disease phenotype (Table III).
PHARMACOGENETICS
– THE CASE FOR RHEUMATOID ARTHRITIS
A particular application of gene polymorphism studies is
the emerging field of pharmacogenetics or pharmacoge-
nomics. This emerging and promising science is com-
mitted with the definition of how gene polymorphism
may influence the several pharmacological aspects of
a certain drug, including pharmacokinetics, pharmaco-
dynamics, and side effects (Marsh and McLeod 2006,
Eichelbaum et al. 2006). A large amount of studies has
been dedicated to this kind of investigation, and several
clinical applications are already available.
Several anti-depressants are metabolized by cyto-
chrome P450 (CYP) enzymes in the liver. It has been
demonstrated that polymorphism in CYP 2C19 and
2D6 is associated with the metabolic rate of venlafax-
ine, amitriptyline, and risperidone (Eichelbaum et al.
2006, van der Weide et al. 2005). Polymorphism in
these genes has been shown to influence drastically the
metabolic rate and therefore the effectiveness and tox-
icity of these drugs. Gene polymorphism influence on
therapeutics has been also shown to be relevant to several
other conditions, such as cancer, osteoporosis, essential
hypertension, and dyslipidemias (Rodriguez-Antona and
Ingelman-Sundberg 2006, Carbonell-Sala et al. 2005,
Arnett et al. 2006, Schmitz and Langmann 2006).
Pharmacogenomics has been applied also to sys-
temic autoimmune diseases. In fact, this field is rather
complex and has great potential, as can be exemplified by
studies carried on in rheumatoid arthritis. Methotrexate
(MTX) has been largely used for this disease and has been
shown to be effective in 46 to 65% of the cases (Bathon
et al. 2000). Toxicity of MTX leading to discontinu-
ation of treatment in RA varies from 10 to 30% (Alar-
con et al. 1989). It is possible that gene polymorphism
may be correlated to some extent with the effectiveness
and toxicity of this drug in RA patients. MTX is a fo-
late analog and acts as a competitive inhibitor of the en-
zyme dihydrofolate reductase (DHFR). Reduced folate
carrier 1 (RFC-1) mediates MTX entry to cells. MTX
efflux from the cell is mediated by the ATP-binding cas-
sette (ABC) transporters (ABCC 1-4 and ABCG2). In-
tracellular MTX is converted into a polyglutamate form
by the enzyme folylpolyglutamyl synthase (FPGS). The
polyglutamate forms of MTX (MTXPG2-7) remain in-
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TABLE IIIGene polymorphism association with susceptibility and phenotype of autoimmune diseases.
Association with susceptibility
Gene and allele Clinical condition Reference
HLA-DQ2 & DQ-8 Celiac Disease Lundin 2003
PTPN22 1858T RA, SLE, GD, type 1 DM and JIA Lee et al. 2007
DRB1*07 / CTLA-4 49G Graves Disease Kula et al 2006
GSTM1 null genotype RA Morinobu et al. 2006
CTLA-4*G allele type 1 DM Kavvoura and Ioannidis 2005
Desmoglein 1 809C allele Pemphigus foliaceus Martel al. 2002
MBL HYPA haplotype Primary biliary cirrhosis Matsushita et al. 2001
Association with disease phenotype
Gene and allele Clinical condition Reference
CTLA-4 +49A allele Extra-glandular Sjögren’s syndrome Downie-Doyle et al. 2006
IL4 Receptor V50 allele Erosive rheumatoid arthritis Prots et al. 2006
FCγRIIIB (few copies) Nephritis in SLE Aitman et al. 2006
ACE D allele Macrovascular disease in SSc Guiducci et al. 2006
IL-1α –889T allele Lack of response to cyclophosphamide in SSc Beretta et al. 2007
CCR5 59029G allele Nephropathy in type 1 DM Mlynarski et al. 2005
RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; GD: Grave’s disease; DM: diabetes mellitus; JIA: juvenile
idiopathic arthritis; MBL: mannose binding lectin; ACE: angiotensin converting enzyme; SSc: systemic sclerosis.
side the cell and inhibit DHFR, which reduces dihydrofo-
late (DHF) to tetrahydrofolate (THF), and thereby affects
the cellular folate pool. MTXPGs also inhibit thymidy-
late synthase (TYMS), which converts deoxyuridylate
to deoxythymidylate in the de novo pyrimidine biosyn-
thetic pathway (Dervieux et al. 2004a). Methylenete-
trahydrofolate reductase (MTHFR) is indirectly in-
hibited by MTX, by means of the effects of MTX on
the intracellular folate pool. MTX effect on the purine
synthesis ultimately increases the intracellular adenosine
pool, which is a potent anti-inflammatory agent. Poten-
tially relevant gene polymorphisms refer to genes that
influence MTX transport across cell membrane and
those involved in intracellular MTX pathway. RFC-1
G80A polymorphism has been associated to the effec-
tiveness of MTX uptaken by cells. Higher MTXPG
levels have been reported in RA patients with the RFC
80A/A genotype as compared with those who had the
RFC 80G/G or G/A genotypes (P< 0.007) (Dervieux et
al. 2004a). Accordingly, the G80A SNP has been pos-
itively associated with a better response to MTX in 105
patients with RA (Dervieux et al. 2004b). SNPs have
been reported for several members of the ABC family
of transporters, some of which are involved in MTX ef-
flux from the intracellular compartment. A recent study
on the ABCB1 gene has found that patients with the
3435CC and 3435CT genotypes had a greater risk of
having active RA compared with patients with the
3435TT genotype. The 3435T allele also seemed to
confer a protective effect, with patients homozygous for
this allele having a less severe form of RA that was
more likely to respond to MTX and prednisone (Paw-
lik et al. 2004). Genetic variations in other members of
the ABC family are quite common and shall be explored
in the context of RA and MTX treatment.
The metilenetetrahidrofolate reductase (MTHFR) is
the best studied of the genes in the MTX cellular pathway.
MTHFR is important in the generation of 5-methyl-THF,
which is the methyl donor for the methylation of ho-
mocysteine to methionine by methionine synthase (MS).
Among several others, two non-synonymous SNPs have
been extensively studied. The C677T polymorphism is
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associated with homocystein plasma concentration and
seems to be associated with MTX toxicity, especially
with hepatotoxicity. On the other hand, the A1298C
polymorphism seems to have no effect on MTX toxi-
city, but seems to be associated with MTX efficacy in
RA patients (Urano et al. 2002).
Thymidilate synthase (TYMS) is a key enzyme in
the de novo thymidylate synthesis (conversion of dUMP
into dTMP). TYMS is inhibited directly by MTXPGs
and indirectly by the folate cofactor depletion induced
by MTX. Two relevant TYMS polymorphisms have been
studied with respect to MTX in RA patients. A poly-
morphic tandem repeat sequence in the 5’-untranslated
region (5’-UTR) correlates with TYMS mRNA expres-
sion. Patients homozygous for the triple repeat allele
(TSER*3/*3) have higher TYMS mRNA expression than
those homozygous for a double repeat allele (TSER*2/
*2). Another relevant polymorphism consists of a 6-bp
deletion of the sequence TTAAAG at nucleotide 1494 in
the 3’-UTR (3’-UTR 6-bp deletion). Apparently the 3’-
UTR deletion is associated with decreased TYMS mRNA
stability and expression. Preliminary evidence suggests
that the TSER*3/*3 polymorphism (increased TYMS
expression) lowered MTX efficacy and the 3’-UTR 6-
bp deletion (decreased TYMS expression) made RA pa-
tients more sensitive to MTX (Kumagai et al. 2003).
Several other genes may affect MTX efficacy and
toxicity, including AMP-activated protein kinase acti-
vator (AICAR), transformylase, γ -glutamyl hydrolase
(GGH), dihydrofolate reductase (DHFR), methionine
synthase (MS), methionine synthase reductase (MTRR)
and serine hydroxymethyltransferase (SHMT). Eventu-
ally, the concomitant analysis of the polymorphism in
several of these genes will provide an appropriate esti-
mate of the expected therapeutic effect and toxicity of
MTX in a given RA patient (Dervieux et al. 2004b).
Tumor necrosis factor (TNF) antagonists have been
shown to be a rather effective therapeutic alternative for
some patients with RA, Crohn’s disease, psoriatic arthri-
tis and ankylosing spondylitis. However, only up to 60%
of the patients will present a satisfactory response to anti-
TNF therapy. There is a functional bi-allelic polymor-
phism in the TNF-α gene A-308G, in which the A allele
is associated with greater expression of the TNF gene.
Preliminary results have suggested that the G/G pheno-
type is associated with a good response, the A/G pheno-
type is associated with a moderate response, and the A/A
phenotype is associated with therapeutic failure (Seitz et
al. 2007). Although not all investigators have achieved
this clear-cut association, it seems to be a prevalent trend
among most of the studies (Ranganathan 2005).
These few examples are representative of the gen-
eral trend that is quickly expanding to encompass the
several therapeutic agents and pathological conditions
within and outside the field of autoimmunity.
PERSPECTIVES PROVIDED BY NOVEL TECHNIQUES
– THERANOSTICS
The perspectives provided by the novel available tech-
nologies appear to promise a real revolution not only in
diagnostic procedures, but also in the current paradigm
for Medicine itself. The nosologic classification system
as we know it today may be totally reshaped in some
areas of Medicine. Some fields will not undergo radi-
cal changes. For example, a patient with inguinal hernia
will probably have the same diagnosis as today. In con-
trast, the vague diagnosis of SLE may change drastically.
It may happen that we will not even talk of SLE in the
future. Specific immunologic imbalances conditioned
by peculiar sets of gene polymorphisms and character-
ized by defined patterns of immune mediators expres-
sion may be identified within the broad family of pa-
tients nowadays diagnosed as SLE. Each one of these
molecularly defined SLE subsets shall be associated
with a peculiar clinical picture and prognosis. Accord-
ingly, the appropriate therapy will be individualized for
each one of these novel molecular-defined nosologic en-
tities. Eventually, it is possible that efforts will be ad-
dressed to the individual molecular imbalances of each
patient as opposed to the current efforts to classify pa-
tients into pre-defined general nosologic categories. This
trend has been clearly announced as the Individualized
Medicine.
On the top of that, pharmacogenetics will provide
an additional degree of individualization for therapy.
Once the molecular imbalance is defined and the correc-
tive therapeutics is devised, the physician will probably
need to confront the therapeutic options with the patient
gene data bank containing the drug-relevant gene poly-
morphisms for that specific patient. As discussed above,
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TABLE IVFiction patient in year 2097.
• Disequilibrium Th1/Th2 in peripheral blood → 65%
• Depressed proportion of Treg in peripheral blood → 0.5%
• DRB1 gene polymorphism → presence of single copy of *0404 allele
• MBL gene heterozigosity → presence of alleles A and D
• TNF-α gene promoter polymorphism at –308 → allele –308A in double copy
• Homozygosity for allele 131R in FcγRII gene
• Protein tyrosine phosphatase non-receptor 22 (PTPN22) → single copy of 1858T allele
• Decreased Thymus Recent-Emigrant T cells → 15,4678 TREC copies/μg CD4⊕DNA
• Hyperexpression of IL-17, IL-2 and osteoprotegerin
• Acceleration in IFN-γ -induced gene activation sequence in macrophages
for some applications it is already feasible to assess how
polymorphism of individual genes influences the thera-
peutic response to certain drugs. It is quite possible that
the molecular definition of disease condition and thera-
peutics on an individual basis will occur concomitantly in
an interactive fashion. This trend has been termed Ther-
anostics and may dominate the management of patients
in the future (Picard and Bergeron 2002, Jain 2002).
MEDICINE IN YEAR 2097
It seems not risky to forecast that Medicine will change
drastically in the coming decades. Many of the clinical
entities, diagnostic procedures, and therapeutic options
of today shall disappear. Novel paradigms, the emerg-
ing technology, and the evolving clinical practice shall
re-shape each other towards a more individualized
Medicine. In a provocative scenario, one can foresee
the clinical workout of a patient in year 2097 (Table IV).
This may cause wonder and skepticism to some of us
nowadays in the same way that our current medical ap-
proach would have caused if shown to a 1597’s physi-
cian (Table I). This historical perspective is reassuring
in that it lends credibility to the viability of an accom-
plishing future for Medicine. However, a word of cau-
tion must be said with respect to the economical impact
of the current and evolving health care. The constant
progress in medical diagnosis and treatment has gen-
erated genuine cost inflation in the health care system
and has imposed difficult challenges for health care
managers all over the world. Therefore the novel tech-
nologies towards individualized Medicine need to be-
come economically feasible in order to thrive.
RESUMO
O homem tem buscado sucessivas abordagens para o entendi-
mento e manejo das doenças. Partindo de conceitos sobre-
naturais e procedimentos místicos, uma abordagem científica
vigorosa vicejou com base em disciplinas fundamentais como
a anatomia, microbiologia, bioquímica, fisiologia, imunologia,
patologia e farmacologia. O conhecimento integrado resul-
tante contribuiu para a atual classificação das doenças e a forma
com que a Medicina atual é praticada. Apesar deste conside-
rável progresso, esta abordagem é insuficiente quando se trata
de condições inflamatórias sistêmicas, como o lúpus eritema-
toso sistêmico, que abrange condições variando de formas
brandas e pauci-sintomáticas até condições rapidamente fa-
tais. O tratamento dessas condições é frequentemente insufi-
ciente e novas abordagens são necessárias para progresso adi-
cional nessas áreas da Medicina. Um avanço recente foi obtido
no que tange às síndromes auto-inflamatórias hereditárias, nas
quais a dissecção molecular dos defeitos gênicos subjacentes
forneceu direcionamento para terapia orientada a alvos mole-
culares específicos. Esta abordagem é passível de aplicação às
doenças auto-imunes sistêmicas com a compreensão de essas
condições podem ser conseqüência da interação de estímulos
ambientais específicos e uma gama de vários polimorfismos
gênicos interconectados. No escopo dessa transformação, a
aplicação dos princípios de farmacogenéticas poderá contribuir
para o progressivo desenvolvimento de uma Medicina perso-
nalizada vigorosa.
Palavras-chave: auto-imunidade, farmacogenética, polimor-
fismo gênico, síndromes auto-inflamatórias, lúpus eritematoso
sistêmico, artrite reumatóide.
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